Rachel Reece, DPM
Foot Surgery · Bronx, NYNPI 1295236727
Payments from drug & device makers
Across 26 payments — averaging $75.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$653
- Medical Device Business Services, Inc.$490
- Averitas Pharma Inc.$289
- Nevro Corp.$176
- Organogenesis Inc.$125
- GRT US Holding, Inc.$90
- plus $145 from 4 others
What the payments were for
- Travel & lodging$59730%
- Food & beverage$88145%
- Education$49025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 2 | $653 |
| Medical Device Business Services, Inc. | 3 | $490 |
| Averitas Pharma Inc. | 5 | $289 |
| Nevro Corp. | 3 | $176 |
| Organogenesis Inc. | 1 | $125 |
| GRT US Holding, Inc. | 4 | $90 |
| Smith+Nephew | 4 | $62 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Osteomed LLC | 1 | $29 |
| 3M Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,968 in reported general payments places this provider in the 75th percentile of 294 foot surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 85 | $26,844 |
| AmantadineAmantadine Hcl | 60 | $11,600 |
| Fluocinonide | 65 | $5,817 |
| Doxepin Hcl | 68 | $4,895 |
| Clotrimazole | 111 | $4,370 |
| Tavaborole | 80 | $3,948 |
| Fluconazole | 30 | $3,341 |
| Diclofenac Sodium ErDiclofenac Sodium | 39 | $3,281 |
| Lidocaine | 26 | $2,531 |
| Ammonium Lactate | 119 | $2,355 |
| CiclopiroxCiclopirox Olamine | 12 | $1,263 |
| Naproxen Sodium | 11 | $900 |
| NyamycNystatin | 15 | $663 |
| Diclofenac Sodium | 37 | $662 |
| Mupirocin | 16 | $124 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Bronx
- David WongBronx$45K
- Sandra GarciaBronx$6K
- Jian ZhangBronx$4K
- Ronald GubermanRidgewood$337K
- John JackaloneBethpage$66K
- Berdj StepanianWhite Plains$26K
- Lawrence SantiBrooklyn$25K
- David GitlinBayside$24K
- Rick DelmonteNew York$21K
- Corrine RenneFranklin Square$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.